Wilmington, DE (Press Release) – Prelude Thera­peutics Incorporated (Nasdaq: PRLD), a clin­i­cal-stage pre­ci­sion on­col­ogy com­pany, to­day an­nounced that the first patient has been dosed in its first-in-human Phase 1 open-label, multi­center, dose-escalation study of PRT1419 in patients with re­lapsed / re­frac­tory hema­to­logic malig­nan­cies. PRT1419, the Com­pany’s third clin­i­cal can­di­date, is de­signed to be an orally avail­able, potent and sel­ective MCL1 in­hib­i­tor.

The dose escalation portion of the study will be con­ducted across two groups, in­clud­ing in patients with re­lapsed / re­frac­tory high-risk myelo­dys­plastic syn­drome (MDS) and acute myeloid leukemia (AML) (Group A), as well as …